^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PORT-7
i
Other names: PORT-7, TT-4
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Portage
Drug class:
Adenosine A2B receptor antagonist
Related drugs:
over2years
TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
P1/2, N=69, Not yet recruiting, Tarus Therapeutics, Inc. | Initiation date: Sep 2021 --> Dec 2022
Trial initiation date
|
CD4 (CD4 Molecule)
|
PORT-7
almost3years
Adenosine receptor antagonists A2AR (TT-10) and A2BR (TT-4) demonstrate anti-tumor activity in 4T1-induced syngeneic breast cancer mouse model (AACR 2022)
TT-10 & TT-4 alone was superior (p<0.05) to the VC as well as single agent anti-PD-1 in slowing tumor growth, which was further supported by the increase in T-cell activity observed in the end of study TIL analysis. Lastly, striking reductions in MDSC populations were also observed in both TT-10 & TT-4 treated mice, when compared to single agent anti-PD-1 and the VC.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ITGAM (Integrin, alpha M) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
PORT-6 • PORT-7
over3years
TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors (clinicaltrials.gov)
P1/2, N=69, Not yet recruiting, Tarus Therapeutics, Inc.
New P1/2 trial
|
CD4 (CD4 Molecule)
|
PORT-7
Share via
